BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 34533062)

  • 1. HIV And HCV adherence and treatment outcomes among people who inject drugs receiving opioid agonist therapy.
    J Minhas H; Akiyama MJ; Norton BL; Heo M; Arnsten JH; Litwin AH
    AIDS Care; 2022 Oct; 34(10):1229-1233. PubMed ID: 34533062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Initiating HCV treatment with direct acting agents in opioid agonist treatment: When to start for people co-infected with HIV?
    Panagiotoglou D; Krebs E; Min JE; Olding M; Ahamad K; Ti L; Montaner JSG; Nosyk B
    Int J Drug Policy; 2017 Sep; 47():169-176. PubMed ID: 28578865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intensive Models of Hepatitis C Care for People Who Inject Drugs Receiving Opioid Agonist Therapy: A Randomized Controlled Trial.
    Akiyama MJ; Norton BL; Arnsten JH; Agyemang L; Heo M; Litwin AH
    Ann Intern Med; 2019 May; 170(9):594-603. PubMed ID: 30959528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gaps in hepatitis C virus prevention and care for HIV-hepatitis C virus co-infected people who inject drugs in Canada.
    Lanièce Delaunay C; Maheu-Giroux M; Marathe G; Saeed S; Martel-Laferrière V; Cooper CL; Walmsley S; Cox J; Wong A; Klein MB;
    Int J Drug Policy; 2022 May; 103():103627. PubMed ID: 35218989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response to direct-acting antiviral therapy among ongoing drug users and people receiving opioid substitution therapy.
    Macías J; Morano LE; Téllez F; Granados R; Rivero-Juárez A; Palacios R; Ríos M; Merino D; Pérez-Pérez M; Collado A; Figueruela B; Morano A; Freyre-Carrillo C; Martín JM; Rivero A; García F; Pineda JA;
    J Hepatol; 2019 Jul; 71(1):45-51. PubMed ID: 30853642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between depressive symptoms and adherence to direct-acting antivirals: Implications for Hepatitis C treatment among people who inject drugs on medications for opioid use disorder.
    Pericot-Valverde I; Heo M; Niu J; Rennert L; Norton BL; Akiyama MJ; Arnsten J; Litwin AH
    Drug Alcohol Depend; 2022 May; 234():109403. PubMed ID: 35306390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis C Virus Direct-Acting Antiviral Treatment Adherence Patterns and Sustained Viral Response Among People Who Inject Drugs Treated in Opioid Agonist Therapy Programs.
    Heo M; Pericot-Valverde I; Rennert L; Akiyama MJ; Norton BL; Gormley M; Agyemang L; Arnsten JH; Litwin AH
    Clin Infect Dis; 2021 Dec; 73(11):2093-2100. PubMed ID: 33876230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. All-cause mortality before and after DAA availability among people living with HIV and HCV: An international comparison between 2010 and 2019.
    Requena MB; Protopopescu C; Stewart AC; van Santen DK; Klein MB; Jarrin I; Berenguer J; Wittkop L; Salmon D; Rauch A; Prins M; van der Valk M; Sacks-Davis R; Hellard ME; Carrieri P; Lacombe K;
    Int J Drug Policy; 2024 Feb; 124():104311. PubMed ID: 38184902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Untreated alcohol use disorder in people who inject drugs (PWID) in France: a major barrier to HCV treatment uptake (the ANRS-FANTASIO study).
    Barré T; Marcellin F; Di Beo V; Delorme J; Rojas Rojas T; Mathurin P; Protopopescu C; Bailly F; Coste M; Authier N; Carrieri MP; Rolland B
    Addiction; 2020 Mar; 115(3):573-582. PubMed ID: 31595554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rationale, design, and methodology of a trial evaluating three models of care for HCV treatment among injection drug users on opioid agonist therapy.
    Akiyama MJ; Agyemang L; Arnsten JH; Heo M; Norton BL; Schackman BR; Linas BP; Litwin AH
    BMC Infect Dis; 2018 Feb; 18(1):74. PubMed ID: 29426304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Life after hepatitis C cure in HIV-infected people who inject drugs and men who have sex with men treated with direct-acting antivirals in France: Health perceptions and experiences from qualitative and quantitative findings (ANRS CO13 HEPAVIH).
    Mora M; Goodyear T; Marcellin F; Shoveller J; Di Beo V; Calzolaio C; Sogni P; Wittkop L; Zucman D; Poizot-Martin I; Lacombe K; Salmon-Céron D; Knight R; Carrieri P
    J Viral Hepat; 2020 Dec; 27(12):1462-1472. PubMed ID: 32810905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Temporal trends in HCV treatment uptake and success among people who inject drugs in Baltimore, MD since the introduction of direct acting antivirals.
    Coyle CR; Gicquelais RE; Genberg BL; Astemborski J; Falade-Nwulia O; Kirk GD; Thomas DL; Mehta SH
    Drug Alcohol Depend; 2023 Dec; 253():. PubMed ID: 38456165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the Efficacies of Direct-Acting Antiviral Treatment for HCV Infection in People Who Inject Drugs and Non-Drug Users.
    Hsu JT; Hsu PI; Shie CB; Chuah SK; Wu IT; Huang WW; Tang SY; Tsai KF; Kuo LF; Ghose S; Hsu JC; Shih CA
    Medicina (Kaunas); 2022 Mar; 58(3):. PubMed ID: 35334612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. M
    Martel-Laferrière V; Feaster DJ; Metsch LR; Schackman BR; Loignon C; Nosyk B; Tookes H; Behrends CN; Arruda N; Adigun O; Goyer ME; Kolber MA; Mary JF; Rodriguez AE; Yanez IG; Pan Y; Khemiri R; Gooden L; Sako A; Bruneau J
    Trials; 2022 Apr; 23(1):341. PubMed ID: 35461260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parenteral drug use as the main barrier to hepatitis C treatment uptake in HIV-infected patients.
    Rivero-Juarez A; Tellez F; Castaño-Carracedo M; Merino D; Espinosa N; Santos J; Macias J; Paniagua-García M; Zapata-Lopez A; Collado A; Gómez-Vidal MA; Perez-Stachowski J; Muñoz-Medina L; Fernandez-Fuertes E; Rivero A;
    HIV Med; 2019 Jul; 20(6):359-367. PubMed ID: 31006980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low Hepatitis C Reinfection Following Direct-acting Antiviral Therapy Among People Who Inject Drugs on Opioid Agonist Therapy.
    Akiyama MJ; Lipsey D; Heo M; Agyemang L; Norton BL; Hidalgo J; Lora K; Litwin AH
    Clin Infect Dis; 2020 Jun; 70(12):2695-2702. PubMed ID: 31346609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Declining prevalence of current HCV infection and increased treatment uptake among people who inject drugs: The ETHOS Engage study.
    Valerio H; Alavi M; Conway A; Silk D; Treloar C; Martinello M; Milat A; Dunlop A; Murray C; Henderson C; Amin J; Read P; Marks P; Degenhardt L; Stevens A; Prain B; Hayllar J; Reid D; Montebello M; Wade A; Christmass M; Cock V; Dore GJ; Grebely J;
    Int J Drug Policy; 2022 Jul; 105():103706. PubMed ID: 35533635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors and HCV treatment outcomes associated with smoking among people who inject drugs on opioid agonist treatment: secondary analysis of the PREVAIL randomized clinical trial.
    Pericot-Valverde I; Heo M; Akiyama MJ; Norton BL; Agyemang L; Niu J; Litwin AH
    BMC Infect Dis; 2020 Dec; 20(1):928. PubMed ID: 33276738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of hepatitis C virus/HIV coinfection among people who use drugs in the era of direct-acting antiviral-based therapy.
    Taylor LE; Swan T; Matthews GV
    Clin Infect Dis; 2013 Aug; 57 Suppl 2(Suppl 2):S118-24. PubMed ID: 23884059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modeling hepatitis C micro-elimination among people who inject drugs with direct-acting antivirals in metropolitan Chicago.
    Tatara E; Gutfraind A; Collier NT; Echevarria D; Cotler SJ; Major ME; Ozik J; Dahari H; Boodram B
    PLoS One; 2022; 17(3):e0264983. PubMed ID: 35271634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.